Clinical Trials Logo

Merkel Cell Carcinoma clinical trials

View clinical trials related to Merkel Cell Carcinoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04596033 Terminated - Clinical trials for Non-small Cell Lung Cancer

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Start date: November 11, 2020
Phase: Phase 1
Study type: Interventional

TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, Genocea confirms which cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune cells that recognize these cancer proteins are multiplied many times (a process called PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in one or more intravenous (IV) infusions.

NCT ID: NCT04590781 Terminated - Clinical trials for Small Cell Lung Cancer

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Start date: May 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in participants with metastatic Merkel cell (MCC) or locoregional MCC that has recurred after locoregional therapy with surgery and/or radiation therapy, and mAb18087 monotherapy in participants with extensive-stage small cell lung cancer (SCLC) that has progressed after standard therapies. This study was terminated by the sponsor. No participants enrolled in Part B.

NCT ID: NCT04187872 Terminated - Clinical trials for Hepatocellular Carcinoma

LITT and Pembrolizumab in Recurrent Brain Metastasis

TORCH
Start date: January 10, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).

NCT ID: NCT04106167 Terminated - Colorectal Cancer Clinical Trials

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Start date: June 11, 2019
Phase:
Study type: Observational

Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

NCT ID: NCT03988647 Terminated - Clinical trials for Merkel Cell Carcinoma

Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma

Start date: July 24, 2019
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to assess 1) the safety and 2) efficacy of combining Anti-PD-1/PD-L1 blockade with palliative radiation therapy in patients with Stage IV Merkel Cell Carcinoma.

NCT ID: NCT03901573 Terminated - Melanoma Clinical Trials

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Start date: December 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)

NCT ID: NCT03853317 Terminated - Clinical trials for Merkel Cell Carcinoma

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Start date: February 24, 2020
Phase: Phase 2
Study type: Interventional

Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients will receive treatment for a maximum of two years.

NCT ID: NCT03435640 Terminated - Colorectal Cancer Clinical Trials

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

REVEAL
Start date: March 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable toxicity, death, or disease progression per RECIST 1.1. Based on Phase 1 results of the study, the decision was made not to start the Phase 2 part of the study and the study was terminated.

NCT ID: NCT02890368 Terminated - Melanoma Clinical Trials

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Start date: September 2016
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase. The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor activity of TTI-621 will be evaluated in combination with other anti-cancer agents or radiation.

NCT ID: NCT02054884 Terminated - Clinical trials for Merkel Cell Carcinoma

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Start date: October 25, 2013
Phase: Phase 2
Study type: Interventional

There is no standard treatment for Merkel cell carcinoma(MCC), as no randomized trials have been conducted to establish standard of care. Despite a sizable number of objective responses induced by combination cyototoxic chemotherapy, a prolongation of patients overall survival has never been demonstrated. This open-label, randomized, double-arm, multi-centre, phase II study of F16IL2 in combination with paclitaxel versus paclitaxel monotherapy, proposes to test the therapeutic efficacy of F16IL2 plus paclitaxel in patients with metastatic Merkel cell carcinoma, who are not amenable to surgery. A total of 90 patients with Merkel cell carcinoma will be enrolled and treated during the study; 45 patients will receive the combination treatment of F16IL2 and paclitaxel (Arm A), and 45 patients will receive paclitaxel monotherapy (Arm B).